701. Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long‐term clinical endpoint. (9th September 2021) Authors: Garcia Barrado, Leandro; Burzykowski, Tomasz; Legrand, Catherine; Buyse, Marc Journal: Pharmaceutical statistics Issue: Volume 21:Number 1(2022) Page Start: 209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
702. Using Bayesian analysis in repeated preclinical in vivo studies for a more effective use of animals. (29th March 2016) Authors: Walley, Rosalind; Sherington, John; Rastrick, Joe; Detrait, Eric; Hanon, Etienne; Watt, Gillian Journal: Pharmaceutical statistics Issue: Volume 15:Number 3(2016) Page Start: 277 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
703. Using marginal structural models to analyze the impact of subsequent therapy on the treatment effect in survival data: Simulations and clinical trial examples. (27th April 2021) Authors: Xu, Qing; Przepiorka, Donna Journal: Pharmaceutical statistics Issue: Volume 20:Number 6(2021) Page Start: 1088 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
704. Using multiple imputation to estimate cumulative distribution functions in longitudinal data analysis with data missing at random. (4th July 2013) Authors: Dinh, Phillip Journal: Pharmaceutical statistics Issue: Volume 12:Number 5(2013:Sep./Oct.) Page Start: 260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
705. Using recurrent time‐to‐event models with multinomial outcomes to generate toxicity profiles. (17th March 2021) Authors: Gebski, Val; Marschner, Ian; Asher, Rebecca; Byth, Karen Journal: Pharmaceutical statistics Issue: Volume 20:Number 4(2021) Page Start: 840 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
706. Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation. (2nd November 2021) Authors: Waterhouse, Brian; Hartford, Alan; Mukhopadhyay, Saurabh; Ferguson, Ryan; Hendrickson, Barbara A. Journal: Pharmaceutical statistics Issue: Volume 21:Number 2(2022) Page Start: 372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
707. Utility values in health technology assessments: a statistician's perspective. (2nd April 2014) Authors: Whately‐Smith, Caroline; Watkins, Claire; Mann, Helen; Fletcher, Chrissie; Ducournau, Pierre Journal: Pharmaceutical statistics Issue: Volume 13:Number 3(2014:May/Jun.) Page Start: 184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
708. Utilizing Bayesian predictive power in clinical trial design. (8th October 2020) Authors: Harari, Ofir; Hsu, Grace; Dron, Louis; Park, Jay J. H.; Thorlund, Kristian; Mills, Edward J. Journal: Pharmaceutical statistics Issue: Volume 20:Number 2(2021) Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
709. Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments. (21st February 2022) Authors: Huang, Bo; Tian, Lu Journal: Pharmaceutical statistics Issue: Volume 21:Number 5(2022) Page Start: 865 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
710. Validation of qualitative microbiological test methods. (21st November 2014) Authors: IJzerman‐Boon, Pieta C.; van den Heuvel, Edwin R. Journal: Pharmaceutical statistics Issue: Volume 14:Number 2(2015:Mar./Apr.) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗